Beta-Adrenergic Agents Long- and Short-Acting (Inhaled)

The classification "Beta-Adrenergic Agents Long- and Short-Acting (Inhaled)" functions primarily as a formulary and administrative grouping that encompasses both short-acting (SABA) and long-acting (LABA) inhaled beta-2 adrenergic receptor agonists

The classification "Beta-Adrenergic Agents Long- and Short-Acting (Inhaled)" functions primarily as a formulary and administrative grouping that encompasses both short-acting (SABA) and long-acting (LABA) inhaled beta-2 adrenergic receptor agonists

These bronchodilator agents stimulate beta-2 adrenergic receptors in airway smooth muscle to increase intracellular cyclic AMP, resulting in muscle relaxation and widened airways Clinically, short-acting formulations provide rapid relief for acute bronchospasm, while long-acting agents deliver extended airway maintenance Together, they represent standard therapies used primarily in the management and prevention of airflow limitation in asthma and chronic obstructive pulmonary disease (COPD)

These bronchodilator agents stimulate beta-2 adrenergic receptors in airway smooth muscle to increase intracellular cyclic AMP, resulting in muscle relaxation and widened airways